Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robin Marie Joyce, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Koshy AG, Kim HT, Liegel J, Arnason JE, Ho VT, Antin JH, Joyce R, Cutler CS, Gooptu M, Nikiforow S, Logan EK, Elavalakanar P, Narcis M, Stroopinsky D, Avigan ZM, Boussi L, Stephenson SL, El Banna H, Bindal P, Cheloni G, Avigan DE, Soiffer RJ, Rosenblatt J. Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease. Blood. 2023 Mar 02. PMID: 36862975.
    Citations:    Fields:    
  2. Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen ED, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Jacene H, Park H, Dahi PB, Nieto Y, Joyce R, Chen YB, Shipp MA, Herrera AF, Armand P. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2022 Nov 18. PMID: 36399518.
    Citations:    Fields:    
  3. Taranto E, Redd R, Jeter E, McHugh K, Crombie JL, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Odejide OO, Dahi PB, Nieto Y, Joyce RM, Chen YB, Bonjoc KC, Chaudhry A, Herrera AF, Armand P, Merryman RW. Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2022 12; 63(12):2912-2917. PMID: 35938581.
    Citations:    Fields:    Translation:HumansCells
  4. Weinstock M, Elavalakanar P, Bright S, Ambati SR, Brouwer-Visser J, Pourpe S, Fiaschi N, Jankovic V, Thurston G, Deering RP, Chaudhry A, Joyce R, Arnason J. Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy. Br J Haematol. 2022 11; 199(3):366-370. PMID: 35892294; PMCID: PMC9796753.
    Citations:    Fields:    
  5. Merryman RW, Redd R, Jeter E, Wong JL, McHugh K, Reynolds C, Nazzaro M, Varden A, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Dahi PB, Nieto Y, Joyce RM, Chen YB, Herrera AF, Armand P, Ritz J. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10. PMID: 34670169; PMCID: PMC8792205.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  6. Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet Haematol. 2021 Nov; 8(11):e818-e827. PMID: 34634256.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  7. Rahimian M, Warner JL, Salmi L, Rosenbloom ST, Davis RB, Joyce RM. Open notes sounds great, but will a provider's documentation change? An exploratory study of the effect of open notes on oncology documentation. JAMIA Open. 2021 Jul; 4(3):ooab051. PMID: 34661067; PMCID: PMC8518311.
    Citations:    
  8. Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 03 23; 5(6):1648-1659. PMID: 33710337; PMCID: PMC7993097.
    Citations: 7     Fields:    Translation:Humans
  9. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 09; 35(9):2672-2683. PMID: 33658659.
    Citations: 9     Fields:    Translation:Humans
  10. Patell R, Khan AM, Bogue T, Merrill M, Koshy A, Bindal P, Joyce R, Aird WC, Neuberg D, Bauer KA, Zwicker JI. Heparin induced thrombocytopenia antibodies in Covid-19. Am J Hematol. 2020 Jul 13. PMID: 32658337; PMCID: PMC7405086.
    Citations: 21     Fields:    
  11. Zwicker JI, Roopkumar J, Puligandla M, Schlechter BL, Sharda AV, Peereboom D, Joyce R, Bockorny B, Neuberg D, Bauer KA, Khorana AA. Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Blood Adv. 2020 05 26; 4(10):2254-2260. PMID: 32442298.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  12. Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867. PMID: 32126141; PMCID: PMC7065472.
    Citations: 10     Fields:    Translation:Humans
  13. Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Bsat J, Patel SS, Ritz J, Rodig SJ, Shipp MA, Chen YB, Joyce RM. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126. PMID: 31917843; PMCID: PMC6960482.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  14. Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019 08 15; 134(7):606-613. PMID: 31186274.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  15. Rahimian M, Warner JL, Jain SK, Davis RB, Zerillo JA, Joyce RM. Significant and Distinctive n-Grams in Oncology Notes: A Text-Mining Method to Analyze the Effect of OpenNotes on Clinical Documentation. JCO Clin Cancer Inform. 2019 06; 3:1-9. PMID: 31184919; PMCID: PMC6873977.
    Citations: 2     Fields:    Translation:Humans
  16. Dewan AK, Gupta S, Bach DQ, Jadeja S, Granter S, LaCasce A, Joyce R, Davids MS, Huang V, LeBoeuf NR. Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition. JAAD Case Rep. 2019 May; 5(5):401-405. PMID: 31049381; PMCID: PMC6479163.
    Citations: 1     
  17. Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174. PMID: 30967392.
    Citations: 10     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  18. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29. PMID: 30952672; PMCID: PMC6609955.
    Citations: 42     Fields:    Translation:HumansCTClinical Trials
  19. Wu PA, Stern RS, Huang V, Liu KX, Chen CA, Tzachanis D, Joyce RM, Davis RB, Ho VT. Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation. J Invest Dermatol. 2019 03; 139(3):591-599. PMID: 30316899.
    Citations: 5     Fields:    Translation:Humans
  20. Nahas MR, Soiffer RJ, Kim HT, Alyea EP, Arnason J, Joyce R, Antin JH, Ho VT, Stroopinsky D, Li S, Levine JD, McMasters M, Jain S, Hamdan A, Tzachanis D, Bryant MP, Logan EK, Bazemore J, Stewart J, Joyce A, Stephenson S, Washington A, Cole L, Pyzer A, Leaf RK, Avigan DE, Rosenblatt J. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018 06 21; 131(25):2836-2845. PMID: 29549175.
    Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
  21. Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 2018 01 15; 124(2):306-314. PMID: 28960265; PMCID: PMC8167813.
    Citations: 12     Fields:    Translation:Humans
  22. Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, Ganjoo KN, Bartlett NL, Lemieux B, VanderWalde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol. 2017 07; 178(2):250-256. PMID: 28419413; PMCID: PMC5737737.
    Citations: 9     Fields:    Translation:Humans
  23. Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant MP, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi PP, Kufe D, Rosenblatt J, Avigan D. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017 Mar 30; 129(13):1791-1801. PMID: 28126925; PMCID: PMC5813734.
    Citations: 61     Fields:    Translation:HumansAnimalsCells
  24. Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171. PMID: 27928025; PMCID: PMC5800949.
    Citations: 72     Fields:    Translation:HumansCellsPHPublic Health
  25. Sells RE, Chen CA, Wong MT, Zimarowski MJ, Kirby JE, Joyce RM, Wu PA. Continuous positive airway pressure-associated cutaneous amoebiasis in an immunosuppressed patient. Br J Dermatol. 2016 Mar; 174(3):625-8. PMID: 26474324.
    Citations:    Fields:    Translation:HumansAnimals
  26. Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, LaCasce AS, Jacobson C, Davids MS, Brown JR, Weng L, Wilkins J, Faham M, Freedman AS, Joyce R, Jacobsen ED. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr; 173(1):89-95. PMID: 26729345.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  27. Jain S, Stroopinsky D, Yin L, Rosenblatt J, Alam M, Bhargava P, Clark RA, Kupper TS, Palmer K, Coll MD, Rajabi H, Pyzer A, Bar-Natan M, Luptakova K, Arnason J, Joyce R, Kufe D, Avigan D. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2015 Jul 16; 126(3):354-62. PMID: 26048911; PMCID: PMC4504948.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  28. Chopra SS, Leshchiner I, Duzkale H, McLaughlin H, Giovanni M, Zhang C, Stitziel N, Fingeroth J, Joyce RM, Lebo M, Rehm H, Vuzman D, Maas R, Sunyaev SR, Murray M, Cassa CA. Inherited CHST11/MIR3922 deletion is associated with a novel recessive syndrome presenting with skeletal malformation and malignant lymphoproliferative disease. Mol Genet Genomic Med. 2015 Sep; 3(5):413-23. PMID: 26436107.
    Citations: 6     Fields:    
  29. Arnason JE, Luptakova K, Rosenblatt J, Tzachanis D, Avigan D, Zwicker JI, Levine J, Kim M, Parker JA, Grant B, Joyce RM. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant. Acta Haematol. 2015; 133(4):347-53. PMID: 25677780.
    Citations: 1     Fields:    Translation:Humans
  30. Tzachanis D, Dewar R, Luptakova K, Chang JD, Joyce RM. Primary cardiac burkitt lymphoma presenting with abdominal pain. Case Rep Hematol. 2014; 2014:687598. PMID: 25431699; PMCID: PMC4241305.
    Citations: 2     
  31. Franquet E, Palmer MR, Gifford AE, Selen DJ, Chen YC, Sedora-Roman N, Joyce RM, Kolodny GM, Moss AC. Rifaximin suppresses background intestinal 18F-FDG uptake on PET/CT scans. Nucl Med Commun. 2014 Oct; 35(10):1026-31. PMID: 25076161.
    Citations: 9     Fields:    Translation:Humans
  32. Tapper EB, Luptakova K, Joyce RM, Tzachanis D. A 78-year-old man with acute myeloid leukemia (AML) and acute renal failure. Am J Case Rep. 2014 Aug 30; 15:364-7. PMID: 25184701.
    Citations: 2     Fields:    Translation:Humans
  33. Ho VT, Kim HT, Kao G, Cutler C, Levine J, Rosenblatt J, Joyce R, Antin JH, Soiffer RJ, Ritz J, Avigan D, Alyea EP. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec; 89(12):1092-6. PMID: 25132538.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  34. Bogusz AM, Joyce R, Kolodny G, Buck T, Pihan G, Bhargava P. An unusual patient with shortness of breath--clinical, radiologic, and pathologic pitfalls. Am J Hematol. 2014 May; 89(5):558-63. PMID: 24496963.
    Citations:    Fields:    Translation:Humans
  35. Brook OR, Mullan CP, Mendiratta-Lala M, Joyce R, Sheiman R, Brook A, Siewert B. Pancreatic atrophy in patients with chronic graft-versus-host disease. Abdom Imaging. 2014 Apr; 39(2):342-7. PMID: 24441578.
    Citations: 3     Fields:    Translation:Humans
  36. Tzachanis D, Hamdan A, Uhlmann EJ, Joyce RM. Successful treatment of refractory Guillain-Barré syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia. Acta Haematol. 2014; 132(2):240-3. PMID: 24853856.
    Citations: 4     Fields:    Translation:HumansCells
  37. Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, Vasir B, Kufe T, Luptakova K, Arnason J, Nardella C, Levine JD, Joyce RM, Galinsky I, Reiter Y, Stone RM, Pandolfi PP, Kufe D, Avigan D. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013 Sep 01; 73(17):5569-79. PMID: 23867470.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  38. Sengupta S, Tarsy D, Joyce R, Jeyapalan S. Novel use of dual immunomodulation for treating stiff-person syndrome, cerebellar variant. Mov Disord. 2013 Nov; 28(13):1905-6. PMID: 23839936.
    Citations: 1     Fields:    Translation:Humans
  39. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 2013 Jul 25; 122(4):499-506. PMID: 23692856; PMCID: PMC3724189.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  40. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8. PMID: 23685836.
    Citations: 87     Fields:    Translation:HumansCellsPHPublic Health
  41. Warner JL, Alterovitz G, Bodio K, Joyce RM. External phenome analysis enables a rational federated query strategy to detect changing rates of treatment-related complications associated with multiple myeloma. J Am Med Inform Assoc. 2013 Jul-Aug; 20(4):696-9. PMID: 23515788.
    Citations: 7     Fields:    Translation:Humans
  42. Shaughnessy P, Uberti J, Devine S, Maziarz RT, Vose J, Micallef I, Jacobsen E, McCarty J, Stiff P, Artz A, Ball ED, Berryman R, Dugan M, Joyce R, Hsu FJ, Johns D, McSweeney P. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplant. 2013 Jun; 48(6):777-81. PMID: 23178544.
    Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
  43. Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, Armand P, Joyce R, Sohani AR, Rodig SJ, Neuberg D, Fisher DC, Abramson JS. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013 Apr; 98(4):615-9. PMID: 23144193.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  44. Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, Joyce RM, Levine JD, Anderson KC, Kufe D, Avigan D. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013 Jan; 62(1):39-49. PMID: 22733396.
    Citations: 78     Fields:    Translation:HumansCells
  45. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66. PMID: 22129252; PMCID: PMC3727432.
    Citations: 485     Fields:    Translation:HumansCellsCTClinical Trials
  46. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, Rotem-Yehudar R, Kufe D, Avigan D. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun; 34(5):409-18. PMID: 21577144.
    Citations: 145     Fields:    Translation:HumansCells
  47. Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402. PMID: 21030562; PMCID: PMC3031474.
    Citations: 75     Fields:    Translation:HumansCellsCTClinical Trials
  48. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86. PMID: 20385792; PMCID: PMC3324254.
    Citations: 300     Fields:    Translation:HumansCTClinical Trials
  49. Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother. 2010 Feb-Mar; 33(2):155-66. PMID: 20145548.
    Citations: 15     Fields:    Translation:HumansCells
  50. Rosenblatt J, Bissonnette A, Ahmad R, Wu Z, Vasir B, Stevenson K, Zarwan C, Keefe W, Glotzbecker B, Mills H, Joyce R, Levine JD, Tzachanis D, Boussiotis V, Kufe D, Avigan D. Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplant. 2010 Sep; 45(9):1463-8. PMID: 20081878.
    Citations: 15     Fields:    Translation:HumansCells
  51. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010 Jan 01; 116(1):106-14. PMID: 19890959; PMCID: PMC2916680.
    Citations: 74     Fields:    Translation:HumansCTClinical Trials
  52. Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, Joyce R, Takvorian RW, Fisher DC, Fisher RI, Liesveld J, Marquis D, Neuberg D, Freedman AS. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009 Jun; 145(6):741-8. PMID: 19344412.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  53. Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma. 2008 Oct; 8(5):300-4. PMID: 18854285.
    Citations: 19     Fields:    Translation:HumansCells
  54. Shaulov A, Yue S, Wang R, Joyce RM, Balk SP, Kim HT, Avigan DE, Uhl L, Sackstein R, Exley MA. Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival. Exp Hematol. 2008; 36(4):464-72.
  55. Shaulov A, Yue S, Wang R, Joyce RM, Balk SP, Kim HT, Avigan DE, Uhl L, Sackstein R, Exley MA. Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival. Exp Hematol. 2008 Apr; 36(4):464-72. PMID: 18261838.
    Citations: 14     Fields:    Translation:HumansCells
  56. Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, Cook D, Songer J, Hill J, Kaden BR, Sharon D, Steiss R, Leleu X, Branagan AR, Badros A. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007 Jun 01; 13(11):3320-5. PMID: 17545538.
    Citations: 39     Fields:    Translation:HumansCTClinical Trials
  57. Williams G, Joyce RM, Parker JA. False-positive axillary lymph node on FDG-PET/CT scan resulting from immunization. Clin Nucl Med. 2006 Nov; 31(11):731-2. PMID: 17053400.
    Citations: 16     Fields:    Translation:HumansPHPublic Health
  58. Williams G, Palmer MR, Parker JA, Joyce R. Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin): a case report. Cancer Biother Radiopharm. 2006 Apr; 21(2):101-5. PMID: 16706630.
    Citations: 7     Fields:    Translation:HumansPHPublic Health
  59. Dimitrios Tzachanis, Robin Joyce, Lowell Schnipper. Waldenstrom's Macroglobulinemia. Clinical Hematology, Neal S. Yound, Stanton L. Gerson and Katherine A. High, eds. 2006; 659-666.
  60. Rosenblatt J, Stone R, Wu Z, Vasir B, Deangelo D, Galinsky I, Miller K, Levine JD, Joyce R, Avigan D. Leukemia derived dendritic cells (LDCs) may be ineffective as a cancer vaccine for acute myeloid leukemia (AML). J Clin Oncol. 2005 Jun; 23(16_suppl):2527. PMID: 27945812.
    Citations:    
  61. Antin JH, Guinan EC, Avigan D, Soiffer RJ, Joyce RM, Martin VJ, Molrine DC. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Mar; 11(3):213-22. PMID: 15744240.
    Citations: 12     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  62. Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma. 2004 Sep; 5(2):98-101. PMID: 15453924.
    Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
  63. Schumer ST, Joyce, RM. Radioimmunotherapy for Non-Hodgkin's Lymphoma. Devita VT Jr, Hellman S, Rosenber SR eds Progress in Oncology 2003. 2003; (2003):46-72.
  64. Joyce RM, Regan M, Ottaway J, Umiel T, Tetreault JC, Levine J, McDermott D, Hurley D, Giallombardo N, Smith T, Lamontagne D, Uhl L, Avigan D. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT). Ann Oncol. 2003; 14 Suppl 1:i21-7. PMID: 12736227.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  65. Hsu K and Joyce R. Stomatitis, prevention and treatment. 2003.
  66. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002 May 15; 20(10):2453-63. PMID: 12011122.
    Citations: 228     Fields:    Translation:HumansCTClinical Trials
  67. Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant. 2002; 8(4):198-205. PMID: 12017145.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  68. Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. Curr Pharm Biotechnol. 2001 Dec; 2(4):341-9. PMID: 11762415.
    Citations: 7     Fields:    Translation:HumansAnimals
  69. Exley MA, Tahir SM, Cheng O, Shaulov A, Joyce R, Avigan D, Sackstein R, Balk SP. A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol. 2001 Nov 15; 167(10):5531-4. PMID: 11698421.
    Citations: 63     Fields:    Translation:HumansCells
  70. Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, McDermott D, Levine J, Warren D, McCauley M, Wheeler C, Frei E. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies. Bone Marrow Transplant. 2001 Sep; 28(5):447-54. PMID: 11593317.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  71. Joyce RM, Kraser CN, Tetrealt JC, Giallombardo N, McDermott D, Levine J, Umiel T, Regan M, Hurley D, Uhl L, Avigan D. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant. Eur J Haematol Suppl. 2001 Jul; 64:56-62. PMID: 11486404.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  72. Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplant. 2001 Feb; 27(3):269-78. PMID: 11277174.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  73. C. N. Krasner, R. M. Joyce, E. M. Creaton. . Use of the International Prognostic Index (IPI) in an Academic Medical Center. Proceedings of ASCO. 2001.
  74. T. E. Witzig, C. A. White, L. Gordon, F. Cabanillas, C. Emmanoulides, M. S. Czuczman, RM Joyce, B. Pohlman, N. Bartlett, P. Multani, A. J. Grillo-Lopez, G. A. Wiseman. Response to Zevalin is Superior to Response to Rituximab Regardless of age and Extent of Disease. Proceedings of ASCO. 2001.
  75. Moy B, Joyce R. Hemorrhagic Cystitis. 2000.
  76. Boyd C, Joyce R. Alopecia management. 2000.
  77. Avigan D, Wu Z, Joyce R, Elias A, Richardson P, McDermott D, Levine J, Kennedy L, Giallombardo N, Hurley D, Gong J, Kufe D. Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant. 2000 Jul; 26(2):169-76. PMID: 10918427.
    Citations: 6     Fields:    Translation:HumansCells
  78. V Borges, RM Joyce, L Uhl, T. Smith L. Kennedy, D. Avigan. Docetaxel and Filgrastim provides a safe and effective mobilization regimen prior to High-dose Chemotherapy for breast cancer. Proceedings of ASCO. 2000.
  79. Hurria A, Joyce RM, Come S. Primary care of breast cancer survivors: Patterns of relpase and long-term complication. 2000.
  80. Hurria A, Joyce RM, Come S. Primary care of breast cancer survivors. 2000.
  81. Joyce, RM, Krasner,C. Tetreau, J. Uhl, L, et al. . Rituxan, Ifosfamide, Mitoxantrone and Etoposide with Filgrastim Support, for induction and stem cell mobilization prior to HDC in patients with B-cell Non-Hodgkin’s Lymphoma. Proceedings of ASBMT. 2000.
  82. LI Gordon, G Wiseman, T. Witzig, JL Murray, M Czuczman, RM Joyce, NL Bartlett, PS Multani, A Grillo, C White. Zevalin induces transient neutropenia and B-Cell depletion but does not induce clinically significant hypogammaglobulinemia no serious infection risk. Proceedings of ASCO. 2000.
  83. Avigan D, Wu Z, Gong J, Joyce R, Levine J, Elias A, Richardson P, Milano J, Kennedy L, Anderson K, Kufe D. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin Cancer Res. 1999 Oct; 5(10):2735-41. PMID: 10537336.
    Citations: 4     Fields:    Translation:HumansCells
  84. Borges V, Joyce RM, Kennedy LE, Avigan D. Docetaxel and Filgrastim: A Promising Stem Cell Mobilization Regimen Prior to High-Dose Chemotherapy for Breast Cancer. Proceedings of ASCO. 1999.
  85. Osowski CL, Dix SP, Lynn M, Davidson T, Cohen L, Miyahara T, Sexauer MC, Joyce R, Yeager A, Wingard JR. An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. Support Care Cancer. 1998 Nov; 6(6):511-7. PMID: 9833299.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  86. Anthony MT, Zeigler ZR, Lister J, Raymond JM, Shadduck RK, Kramer RE, Gryn JF, Rintels PB, Besa EC, George JN, Silver B, Joyce R, Bodensteiner D. Plasminogen activator inhibitor (PAI-1) antigen levels in primary TTP and secondary TTP post-bone marrow transplantation. Am J Hematol. 1998 Sep; 59(1):9-14. PMID: 9723570.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  87. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol. 1998 Jan; 159(1):149-53. PMID: 9400459.
    Citations: 34     Fields:    Translation:Humans
  88. Joyce,RM, Come, S. Breast Cancer: Who should be screened and when?. The Consultant. 1996; 36(9):1841-1850.
  89. Hähnel E, Harvey JM, Joyce R, Robbins PD, Sterrett GF, Hähnel R. Stromelysin-3 expression in breast cancer biopsies: clinico-pathological correlations. Int J Cancer. 1993 Nov 11; 55(5):771-4. PMID: 8244574.
    Citations: 7     Fields:    Translation:Humans
  90. Vincent PC, Joyce RM, Croaker G, Young GA, Milton GW, McCarthy WH. Semi-solid cultures of primary melanomas and their correlation with histopathological features. Pathology. 1985 Apr; 17(2):360-4. PMID: 4047740.
    Citations: 1     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Joyce's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (362)
Explore
_
Co-Authors (111)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.